Treatment for small ureteric stones using medication

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of α-blockers, specifically silodosin, as a medical expulsive therapy (MET) for patients with distal ureteric stones (DUS) located in the lower third of the ureter. The study aims to confirm the efficacy and safety of this non-invasive treatment option compared to traditional invasive procedures. Participants will be adults aged 18 to 70 with specific eligibility criteria, including the presence of a single, unilateral, radiopaque ureteral calculus. The trial will assess the therapeutic benefits of α-blockers, which have shown promising results in previous studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults male and female aged 18 to 70 years
* Patients who give informed consent
* Stone located in the distal 1/3rd of ureter (Single, unilateral and radiopaque ureteral calculus 5 to 10 mm visible on the CT-KUB± X-ray KUB within the ureter
* Serum creatinine level within the normal range (adult men, 0.74 to 1.35 mg/dL \& 0.59 to 1.04 mg/dL)
* Ability to tolerate oral fluids and oral pain medication

Exclusion Criteria:

* Patients already taking an alpha-adrenergic antagonist medication for 4 weeks
* Evidence of any other renal stone simultaneously present or at any location
* Hydronephrosis Grade 3 (Moderate) \& Grade 4 (Severe) Patients with eGFR \<60 ml/min/1.73m2
* Signs of infection including temperature \>38ºC or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count \>5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of \>100,000 CFU)
* Patients with chronic pain already undergoing treatment with narcotic medications or drug abusers
* Pregnant or lactating women
* Patient suffering from urinary tract infection, ureteral surgery, and existing DJ stents.
* Clinical jaundice
* Any forms of anatomical obstructions in the urinary tract
* The previously suffering from postural hypotension
* Any other disease jeopardizing participation in trial and could lead to increase patient health risks
* History of allergic reactions with the study drugs (Silodosin or Tamsulosin)

Where it's running

• North west general hospital
  Peshawar, Kpk, Pakistan Recruiting

Study contacts

• Principal investigator: Salman El Khalid, MBBS — The Kidney Centre
• Study coordinator: Dr. Mahaveer N Maheshwari, MBBS
• Email: mahaveer.maheshwari@getzpharma.com
• Phone: +923202521918

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of Ertugliflozin on liver fat and diabetes control in patients with fatty liver disease

  This study is testing if the medication Ertugliflozin can help adults with Type 2 Diabetes and fatty liver disease reduce liver fat and improve their blood sugar control.

  Recruiting Phase 4 Getz Pharma · Peshawar, KPK · NCT05644717

• Empagliflozin with or without metformin for safety and tolerability in adults with Type 2 diabetes

  This project will try empagliflozin, with or without metformin, in adults with Type 2 diabetes to see if it is safe and well tolerated in routine clinical care at participating centers.

  Recruiting at 2 sites Phase 4 Getz Pharma · Kabul, Afghanistan and 5 other locations · NCT05164263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.